Humanized antibodies

• US 20050090648A1
• Filed: 04/26/2002
• Published: 04/28/2005
• Est. Priority Date: 04/30/2001
• Status: Active Grant

• Current Assignee: Maximiliano J. Vasquez, Naoya Tsurushita
• Original Assignee: Maximiliano J. Vasquez, Naoya Tsurushita
• Inventors: Tsurushita, Naoya, Vasquez, Maximiliano J.
• Granted Patent: US 7,318,923 B2
• Time in Patent Office: Days
• US Class Current: 530/388.26
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down'"'"'s syndrome or pre-clinical or clinical Alzheimer'"'"'s disease or cerebral amyloid angiopathy.

Claims

1-29. -29. (canceled)

30. An antibody comprising the sequence given by SEQ ID NO:

9 and the sequence given by SEQ ID NO;

10.

31. A polynucleotide compound, comprising a sequence coding for either SEQ ID NO:

9 or SEQ ID NO;

10 of the antibody of claim 30.

32. A cell that is capable of expressing the antibody of claim 30.

33. A pharmaceutical composition, comprising the antibody of claim 30 and a pharmaceutically acceptable excipient.

34. A method for treating clinical or pre-clinical Alzheimer'"'"'s disease, Down'"'"'s syndrome, or clinical or pre-clinical amyloid angiopathy in a human subject, comprising administering to the human subject an effective amount of the antibody of claim 30.

35. An antibody comprising a light chain comprising the sequence given by SEQ ID NO:

9 and a heavy chain comprising the sequence given by SEQ ID NO;

10.

36. A polynucleotide compound, comprising a sequence coding for either SEQ ID NO:

9 or SEQ ID NO;

10 of the antibody of claim 35.

37. A cell that is capable of expressing the antibody of claim 35.

38. A pharmaceutical composition, comprising the antibody of claim 35 and a pharmaceutically acceptable excipient.

39. A method for treating clinical or pre-clinical Alzheimer'"'"'s disease, Down'"'"'s syndrome, or clinical or pre-clinical amyloid angiopathy in a human subject, comprising administering to the human subject an effective amount of the antibody of claim 35.

40. The antibody of claim 35 having a light chain of the sequence given by SEQ ID NO:

11 and a heavy chain of the sequence given by SEQ ID NO;

12.

41. A polynucleotide compound, comprising a sequence coding for either SEQ ID NO:

11 or SEQ ID NO;

12 of the antibody of claim 40.

42. A cell that is capable of expressing the antibody of claim 40.

43. A pharmaceutical composition, comprising the antibody of claim 40 and a pharmaceutically acceptable excipient.

44. A method for treating clinical or pre-clinical Alzheimer'"'"'s disease, Down'"'"'s syndrome, or clinical or pre-clinical amyloid angiopathy in a human subject, comprising administering to the human subject an effective amount of the antibody of claim 40.

45. An antibody fragment comprising the sequence given by SEQ ID NO:

9 and the sequence given by SEQ ID NO;

10.

46. The antibody fragment of claim 45, which is an Fab or an F(ab′

)2 fragment.

47. The antibody fragment of claim 45, which is a single chain.

48. A polynucleotide compound, comprising a sequence coding for either SEQ ID NO:

9 or SEQ ID NO;

10 of the antibody fragment of claim 45.

49. A cell that is capable of expressing the antibody fragment of claim 45.

50. A pharmaceutical composition, comprising the antibody fragment of claim 45 and a pharmaceutically acceptable excipient.

51. A method for treating clinical or pre-clinical Alzheimer'"'"'s disease, Down'"'"'s syndrome, or clinical or pre-clinical amyloid angiopathy in a human subject, comprising administering to the human subject an effective amount of the antibody fragment of claim 45.